Unlike existing approved therapies, it simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that early clinical data suggest may produce substantial metabolic effects
CT-388 is an orally or injectably administered dual GLP-1R and GIPR agonist that is in the early stages of development
To get the best outcomes, dermatologists often recommend combining treatments and lifestyle changes
It also stabilizes blood sugar, which normalizes insulin levels, helping to burn fat. Prescriptions will be supported by the comprehensive features of Noom Med, including asynchronous telehealth, access to care coordinators, Noom Weight, premium 1:1 coaching, and medication fulfillment through Nooms partner pharmacies, all enhanced by Nooms Medication Companion with Muscle Defense TM
It is the cleavage product of GLP-1 (1-36) amide peptide
By modulating dopamine levels, these medications could potentially impact the reinforcing effects of addictive behaviors